Common seizure drug could be key to fighting Alzheimer's in down syndrome

NCT ID NCT07234695

Summary

This study is testing whether a medication called levetiracetam, commonly used for seizures, can prevent epileptic seizures in adults with Down syndrome who also have Alzheimer's disease. Researchers also want to see if the drug can slow down the brain changes and memory loss linked to Alzheimer's. About 120 participants will be randomly assigned to receive either the real drug or a placebo for nearly two years, with regular check-ups to monitor their health and brain function.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPILEPSY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fundación CITA Alzheimer

    NOT_YET_RECRUITING

    Donostia / San Sebastian, Basque Country, 20009, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hospital La Princesa

    NOT_YET_RECRUITING

    Madrid, 28006, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hospital Universitario Marqués de Valdecilla

    NOT_YET_RECRUITING

    Santander, Cantabria, 39008, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hospital Virgen de las Nieves

    NOT_YET_RECRUITING

    Granada, Andalusia, 18014, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hospital de la Santa Creu i Sant Pau

    RECRUITING

    Barcelona, Catalonia, 08041, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.